Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
INO-5401 / Inovio
NCT03502785 / 2018-000309-21: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma	Active, not recruiting	1/2	35	US	INO-5401, INO-9012, Atezolizumab, CELLECTRA™ 2000	Inovio Pharmaceuticals	Urothelial Carcinoma	12/24	12/24
NCT03491683: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) From trial in combination with INO-5401 & INO-9012 for 1L GBM Nov 2019 - Nov 2019: From trial in combination with INO-5401 & INO-9012 for 1L GBM	Active, not recruiting	1/2	52	US	INO-5401, INO-9012, Cemiplimab, REGN2810, Radiation Therapy, Temozolomide	Inovio Pharmaceuticals	Glioblastoma	12/24	12/24
NCT04367675: INO 5401 Vaccination in BRCA1/2 Mutation Carriers	Recruiting	1b	44	US	INO-5401, INO-9012, Cellectra 2000	University of Pennsylvania, Inovio Pharmaceuticals	BRCA1/2 Mutation	12/25	12/25